CN110236189A - A kind of composition and its preparation method and application for protecting eyesight - Google Patents
A kind of composition and its preparation method and application for protecting eyesight Download PDFInfo
- Publication number
- CN110236189A CN110236189A CN201910551905.0A CN201910551905A CN110236189A CN 110236189 A CN110236189 A CN 110236189A CN 201910551905 A CN201910551905 A CN 201910551905A CN 110236189 A CN110236189 A CN 110236189A
- Authority
- CN
- China
- Prior art keywords
- core material
- microcapsules
- wall material
- composition
- weight
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 230000004438 eyesight Effects 0.000 title claims abstract description 32
- 239000000203 mixture Substances 0.000 title claims abstract description 32
- 238000002360 preparation method Methods 0.000 title claims abstract description 15
- 239000000463 material Substances 0.000 claims abstract description 60
- 239000011162 core material Substances 0.000 claims abstract description 56
- 239000003094 microcapsule Substances 0.000 claims abstract description 51
- KBPHJBAIARWVSC-XQIHNALSSA-N trans-lutein Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CC(O)CC1(C)C)C=CC=C(/C)C=CC2C(=CC(O)CC2(C)C)C KBPHJBAIARWVSC-XQIHNALSSA-N 0.000 claims abstract description 37
- KBPHJBAIARWVSC-RGZFRNHPSA-N lutein Chemical compound C([C@H](O)CC=1C)C(C)(C)C=1\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\[C@H]1C(C)=C[C@H](O)CC1(C)C KBPHJBAIARWVSC-RGZFRNHPSA-N 0.000 claims abstract description 36
- XOAAWQZATWQOTB-UHFFFAOYSA-N taurine Chemical compound NCCS(O)(=O)=O XOAAWQZATWQOTB-UHFFFAOYSA-N 0.000 claims abstract description 36
- 235000012680 lutein Nutrition 0.000 claims abstract description 33
- 239000001656 lutein Substances 0.000 claims abstract description 33
- 229960005375 lutein Drugs 0.000 claims abstract description 33
- ORAKUVXRZWMARG-WZLJTJAWSA-N lutein Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CCCC1(C)C)C=CC=C(/C)C=CC2C(=CC(O)CC2(C)C)C ORAKUVXRZWMARG-WZLJTJAWSA-N 0.000 claims abstract description 33
- FJHBOVDFOQMZRV-XQIHNALSSA-N xanthophyll Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CC(O)CC1(C)C)C=CC=C(/C)C=CC2C=C(C)C(O)CC2(C)C FJHBOVDFOQMZRV-XQIHNALSSA-N 0.000 claims abstract description 33
- 238000000034 method Methods 0.000 claims abstract description 21
- 229960003080 taurine Drugs 0.000 claims abstract description 18
- 102000004407 Lactalbumin Human genes 0.000 claims abstract description 17
- 108090000942 Lactalbumin Proteins 0.000 claims abstract description 17
- 239000004006 olive oil Substances 0.000 claims abstract description 14
- 235000008390 olive oil Nutrition 0.000 claims abstract description 14
- 239000000084 colloidal system Substances 0.000 claims abstract description 10
- MBMBGCFOFBJSGT-KUBAVDMBSA-N docosahexaenoic acid Natural products CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCC(O)=O MBMBGCFOFBJSGT-KUBAVDMBSA-N 0.000 claims description 20
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 20
- 238000004321 preservation Methods 0.000 claims description 15
- 235000013305 food Nutrition 0.000 claims description 14
- 238000001694 spray drying Methods 0.000 claims description 12
- 239000012153 distilled water Substances 0.000 claims description 10
- 238000003756 stirring Methods 0.000 claims description 10
- 241001494479 Pecora Species 0.000 claims description 7
- 235000010489 acacia gum Nutrition 0.000 claims description 5
- 239000001785 acacia senegal l. willd gum Substances 0.000 claims description 5
- 235000013336 milk Nutrition 0.000 claims description 5
- 239000008267 milk Substances 0.000 claims description 5
- 210000004080 milk Anatomy 0.000 claims description 5
- 102000009027 Albumins Human genes 0.000 claims description 4
- 108010088751 Albumins Proteins 0.000 claims description 4
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 4
- 229920002774 Maltodextrin Polymers 0.000 claims description 4
- 239000005913 Maltodextrin Substances 0.000 claims description 4
- 229920002472 Starch Polymers 0.000 claims description 4
- 229940035034 maltodextrin Drugs 0.000 claims description 4
- 239000008107 starch Substances 0.000 claims description 4
- 108010010803 Gelatin Proteins 0.000 claims description 3
- 229920000159 gelatin Polymers 0.000 claims description 3
- 239000008273 gelatin Substances 0.000 claims description 3
- 235000019322 gelatine Nutrition 0.000 claims description 3
- 235000011852 gelatine desserts Nutrition 0.000 claims description 3
- 101100244345 Dunaliella acidophila DHA1 gene Proteins 0.000 claims description 2
- 239000005862 Whey Substances 0.000 claims description 2
- 102000007544 Whey Proteins Human genes 0.000 claims description 2
- 108010046377 Whey Proteins Proteins 0.000 claims description 2
- 238000004090 dissolution Methods 0.000 claims description 2
- 235000020251 goat milk Nutrition 0.000 claims description 2
- 229910052757 nitrogen Inorganic materials 0.000 claims description 2
- SBJKKFFYIZUCET-JLAZNSOCSA-N Dehydro-L-ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(=O)C1=O SBJKKFFYIZUCET-JLAZNSOCSA-N 0.000 claims 1
- 150000002148 esters Chemical class 0.000 claims 1
- 239000007789 gas Substances 0.000 claims 1
- 125000004365 octenyl group Chemical group C(=CCCCCCC)* 0.000 claims 1
- 239000003921 oil Substances 0.000 abstract description 8
- 235000019198 oils Nutrition 0.000 abstract description 8
- 230000008832 photodamage Effects 0.000 abstract description 5
- 230000008569 process Effects 0.000 abstract description 4
- 230000029087 digestion Effects 0.000 abstract description 2
- 230000000052 comparative effect Effects 0.000 description 36
- 241000700159 Rattus Species 0.000 description 16
- 210000002966 serum Anatomy 0.000 description 15
- 238000005286 illumination Methods 0.000 description 13
- MWUXSHHQAYIFBG-UHFFFAOYSA-N Nitric oxide Chemical compound O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 description 12
- 238000004945 emulsification Methods 0.000 description 11
- 235000020669 docosahexaenoic acid Nutrition 0.000 description 10
- 235000013350 formula milk Nutrition 0.000 description 10
- 229940090949 docosahexaenoic acid Drugs 0.000 description 9
- 239000004615 ingredient Substances 0.000 description 8
- 102000003777 Interleukin-1 beta Human genes 0.000 description 7
- 108090000193 Interleukin-1 beta Proteins 0.000 description 7
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 7
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 7
- 239000004519 grease Substances 0.000 description 7
- 238000002156 mixing Methods 0.000 description 7
- 102000016938 Catalase Human genes 0.000 description 6
- 108010053835 Catalase Proteins 0.000 description 6
- 102000005720 Glutathione transferase Human genes 0.000 description 6
- 108010070675 Glutathione transferase Proteins 0.000 description 6
- 108010074051 C-Reactive Protein Proteins 0.000 description 5
- 102100032752 C-reactive protein Human genes 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 239000003995 emulsifying agent Substances 0.000 description 5
- 239000000843 powder Substances 0.000 description 5
- 210000001525 retina Anatomy 0.000 description 5
- -1 sucrose ester Chemical class 0.000 description 5
- JKQXZKUSFCKOGQ-JLGXGRJMSA-N (3R,3'R)-beta,beta-carotene-3,3'-diol Chemical compound C([C@H](O)CC=1C)C(C)(C)C=1/C=C/C(/C)=C/C=C/C(/C)=C/C=C/C=C(C)C=CC=C(C)C=CC1=C(C)C[C@@H](O)CC1(C)C JKQXZKUSFCKOGQ-JLGXGRJMSA-N 0.000 description 4
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 4
- JKQXZKUSFCKOGQ-LQFQNGICSA-N Z-zeaxanthin Natural products C([C@H](O)CC=1C)C(C)(C)C=1C=CC(C)=CC=CC(C)=CC=CC=C(C)C=CC=C(C)C=CC1=C(C)C[C@@H](O)CC1(C)C JKQXZKUSFCKOGQ-LQFQNGICSA-N 0.000 description 4
- QOPRSMDTRDMBNK-RNUUUQFGSA-N Zeaxanthin Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CCC(O)C1(C)C)C=CC=C(/C)C=CC2=C(C)CC(O)CC2(C)C QOPRSMDTRDMBNK-RNUUUQFGSA-N 0.000 description 4
- JKQXZKUSFCKOGQ-LOFNIBRQSA-N all-trans-Zeaxanthin Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CC(O)CC1(C)C)C=CC=C(/C)C=CC2=C(C)CC(O)CC2(C)C JKQXZKUSFCKOGQ-LOFNIBRQSA-N 0.000 description 4
- 235000018102 proteins Nutrition 0.000 description 4
- 102000004169 proteins and genes Human genes 0.000 description 4
- 108090000623 proteins and genes Proteins 0.000 description 4
- 235000010930 zeaxanthin Nutrition 0.000 description 4
- 239000001775 zeaxanthin Substances 0.000 description 4
- 229940043269 zeaxanthin Drugs 0.000 description 4
- LOGFVTREOLYCPF-KXNHARMFSA-N (2s,3r)-2-[[(2r)-1-[(2s)-2,6-diaminohexanoyl]pyrrolidine-2-carbonyl]amino]-3-hydroxybutanoic acid Chemical compound C[C@@H](O)[C@@H](C(O)=O)NC(=O)[C@H]1CCCN1C(=O)[C@@H](N)CCCCN LOGFVTREOLYCPF-KXNHARMFSA-N 0.000 description 3
- 238000002965 ELISA Methods 0.000 description 3
- 230000004300 dark adaptation Effects 0.000 description 3
- 238000011049 filling Methods 0.000 description 3
- 239000003292 glue Substances 0.000 description 3
- 235000019698 starch Nutrition 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 2
- 208000019155 Radiation injury Diseases 0.000 description 2
- YZXBAPSDXZZRGB-DOFZRALJSA-N arachidonic acid Chemical compound CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O YZXBAPSDXZZRGB-DOFZRALJSA-N 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 150000001720 carbohydrates Chemical class 0.000 description 2
- 235000014633 carbohydrates Nutrition 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- VEVZSMAEJFVWIL-UHFFFAOYSA-O cyanidin cation Chemical compound [O+]=1C2=CC(O)=CC(O)=C2C=C(O)C=1C1=CC=C(O)C(O)=C1 VEVZSMAEJFVWIL-UHFFFAOYSA-O 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 238000000265 homogenisation Methods 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 230000002757 inflammatory effect Effects 0.000 description 2
- 239000011159 matrix material Substances 0.000 description 2
- 235000016709 nutrition Nutrition 0.000 description 2
- 230000035764 nutrition Effects 0.000 description 2
- CKQVRZJOMJRTOY-UHFFFAOYSA-N octadecanoic acid;propane-1,2,3-triol Chemical compound OCC(O)CO.CCCCCCCCCCCCCCCCCC(O)=O CKQVRZJOMJRTOY-UHFFFAOYSA-N 0.000 description 2
- 230000003647 oxidation Effects 0.000 description 2
- 238000007254 oxidation reaction Methods 0.000 description 2
- 230000036542 oxidative stress Effects 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- JQWAHKMIYCERGA-UHFFFAOYSA-N (2-nonanoyloxy-3-octadeca-9,12-dienoyloxypropoxy)-[2-(trimethylazaniumyl)ethyl]phosphinate Chemical compound CCCCCCCCC(=O)OC(COP([O-])(=O)CC[N+](C)(C)C)COC(=O)CCCCCCCC=CCC=CCCCCC JQWAHKMIYCERGA-UHFFFAOYSA-N 0.000 description 1
- DVSZKTAMJJTWFG-SKCDLICFSA-N (2e,4e,6e,8e,10e,12e)-docosa-2,4,6,8,10,12-hexaenoic acid Chemical compound CCCCCCCCC\C=C\C=C\C=C\C=C\C=C\C=C\C(O)=O DVSZKTAMJJTWFG-SKCDLICFSA-N 0.000 description 1
- JLPULHDHAOZNQI-ZTIMHPMXSA-N 1-hexadecanoyl-2-(9Z,12Z-octadecadienoyl)-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCC\C=C/C\C=C/CCCCC JLPULHDHAOZNQI-ZTIMHPMXSA-N 0.000 description 1
- GZJLLYHBALOKEX-UHFFFAOYSA-N 6-Ketone, O18-Me-Ussuriedine Natural products CC=CCC=CCC=CCC=CCC=CCC=CCCCC(O)=O GZJLLYHBALOKEX-UHFFFAOYSA-N 0.000 description 1
- 208000002177 Cataract Diseases 0.000 description 1
- 241000195493 Cryptophyta Species 0.000 description 1
- 229920000858 Cyclodextrin Polymers 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- 206010018473 Glycosuria Diseases 0.000 description 1
- 101000623901 Homo sapiens Mucin-16 Proteins 0.000 description 1
- 101001024605 Homo sapiens Next to BRCA1 gene 1 protein Proteins 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 102100023123 Mucin-16 Human genes 0.000 description 1
- 241001025261 Neoraja caerulea Species 0.000 description 1
- 240000007817 Olea europaea Species 0.000 description 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
- 101000942127 Rattus norvegicus C-reactive protein Proteins 0.000 description 1
- 101000940868 Rattus norvegicus Cysteine and glycine-rich protein 1 Proteins 0.000 description 1
- 208000017442 Retinal disease Diseases 0.000 description 1
- 206010038923 Retinopathy Diseases 0.000 description 1
- HVUMOYIDDBPOLL-XWVZOOPGSA-N Sorbitan monostearate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O HVUMOYIDDBPOLL-XWVZOOPGSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- WERKSKAQRVDLDW-ANOHMWSOSA-N [(2s,3r,4r,5r)-2,3,4,5,6-pentahydroxyhexyl] (z)-octadec-9-enoate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO WERKSKAQRVDLDW-ANOHMWSOSA-N 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000006978 adaptation Effects 0.000 description 1
- 230000003064 anti-oxidating effect Effects 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 229940114079 arachidonic acid Drugs 0.000 description 1
- 235000021342 arachidonic acid Nutrition 0.000 description 1
- 208000003464 asthenopia Diseases 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 239000011648 beta-carotene Substances 0.000 description 1
- 229960002747 betacarotene Drugs 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000005252 bulbus oculi Anatomy 0.000 description 1
- 239000005018 casein Substances 0.000 description 1
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 description 1
- 235000021240 caseins Nutrition 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 230000004087 circulation Effects 0.000 description 1
- 238000013329 compounding Methods 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 235000007336 cyanidin Nutrition 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 235000013325 dietary fiber Nutrition 0.000 description 1
- KAUVQQXNCKESLC-UHFFFAOYSA-N docosahexaenoic acid (DHA) Natural products COC(=O)C(C)NOCC1=CC=CC=C1 KAUVQQXNCKESLC-UHFFFAOYSA-N 0.000 description 1
- 239000003651 drinking water Substances 0.000 description 1
- 235000020188 drinking water Nutrition 0.000 description 1
- 238000005538 encapsulation Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 239000011261 inert gas Substances 0.000 description 1
- 230000008595 infiltration Effects 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 210000002490 intestinal epithelial cell Anatomy 0.000 description 1
- JEIPFZHSYJVQDO-UHFFFAOYSA-N iron(III) oxide Inorganic materials O=[Fe]O[Fe]=O JEIPFZHSYJVQDO-UHFFFAOYSA-N 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 239000000693 micelle Substances 0.000 description 1
- 235000021281 monounsaturated fatty acids Nutrition 0.000 description 1
- 235000021590 normal diet Nutrition 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 235000020777 polyunsaturated fatty acids Nutrition 0.000 description 1
- 238000003672 processing method Methods 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000004243 retinal function Effects 0.000 description 1
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 1
- 210000000813 small intestine Anatomy 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 235000011076 sorbitan monostearate Nutrition 0.000 description 1
- 239000001587 sorbitan monostearate Substances 0.000 description 1
- 229940035048 sorbitan monostearate Drugs 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 229940083466 soybean lecithin Drugs 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23C—DAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; MAKING THEREOF
- A23C9/00—Milk preparations; Milk powder or milk powder preparations
- A23C9/152—Milk preparations; Milk powder or milk powder preparations containing additives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23C—DAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; MAKING THEREOF
- A23C9/00—Milk preparations; Milk powder or milk powder preparations
- A23C9/152—Milk preparations; Milk powder or milk powder preparations containing additives
- A23C9/1526—Amino acids; Peptides; Protein hydrolysates; Nucleic acids; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23C—DAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; MAKING THEREOF
- A23C9/00—Milk preparations; Milk powder or milk powder preparations
- A23C9/152—Milk preparations; Milk powder or milk powder preparations containing additives
- A23C9/1528—Fatty acids; Mono- or diglycerides; Petroleum jelly; Paraffine; Phospholipids; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L29/00—Foods or foodstuffs containing additives; Preparation or treatment thereof
- A23L29/03—Organic compounds
- A23L29/045—Organic compounds containing nitrogen as heteroatom
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L29/00—Foods or foodstuffs containing additives; Preparation or treatment thereof
- A23L29/20—Foods or foodstuffs containing additives; Preparation or treatment thereof containing gelling or thickening agents
- A23L29/206—Foods or foodstuffs containing additives; Preparation or treatment thereof containing gelling or thickening agents of vegetable origin
- A23L29/25—Exudates, e.g. gum arabic, gum acacia, gum karaya or tragacanth
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L29/00—Foods or foodstuffs containing additives; Preparation or treatment thereof
- A23L29/20—Foods or foodstuffs containing additives; Preparation or treatment thereof containing gelling or thickening agents
- A23L29/275—Foods or foodstuffs containing additives; Preparation or treatment thereof containing gelling or thickening agents of animal origin, e.g. chitin
- A23L29/281—Proteins, e.g. gelatin or collagen
- A23L29/284—Gelatin; Collagen
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L29/00—Foods or foodstuffs containing additives; Preparation or treatment thereof
- A23L29/30—Foods or foodstuffs containing additives; Preparation or treatment thereof containing carbohydrate syrups; containing sugars; containing sugar alcohols, e.g. xylitol; containing starch hydrolysates, e.g. dextrin
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L29/00—Foods or foodstuffs containing additives; Preparation or treatment thereof
- A23L29/30—Foods or foodstuffs containing additives; Preparation or treatment thereof containing carbohydrate syrups; containing sugars; containing sugar alcohols, e.g. xylitol; containing starch hydrolysates, e.g. dextrin
- A23L29/35—Degradation products of starch, e.g. hydrolysates, dextrins; Enzymatically modified starches
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/115—Fatty acids or derivatives thereof; Fats or oils
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/17—Amino acids, peptides or proteins
- A23L33/175—Amino acids
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23P—SHAPING OR WORKING OF FOODSTUFFS, NOT FULLY COVERED BY A SINGLE OTHER SUBCLASS
- A23P10/00—Shaping or working of foodstuffs characterised by the products
- A23P10/30—Encapsulation of particles, e.g. foodstuff additives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Abstract
The invention discloses a kind of compositions and its preparation method and application for protecting eyesight, and the composition includes the component of following parts by weight: lutein 0.1~5, taurine 1~10, DHA 1~15, olive oil 1~15.Microcapsules based on the composition are made of core material and wall material, the parts by weight of the core material and wall material are as follows: core material 20~60, wall material 40~80;The core material is composition described in claim 1;The wall material is made of colloid and lactalbumin, and the mass percentage content of lactalbumin is 20~50% in the wall material.The composition of protection eyesight of the present invention has superior protection vision performance.Core material has not only acted as the synergy for resisting blue light damage in the microcapsules being fabricated to, and also improves the bioavailability of lutein.The wall materials of microcapsules selects colloid and lactalbumin to combine, and not only embedding rate is high (embedding rate up to 92%), and film forming is good when dry, and surface oil is low, and core material rate of release in enteron aisle digestion process is reasonable.
Description
Technical field
The invention belongs to food technology fields, and in particular to a kind of composition and preparation method thereof for protecting eyesight and answer
With.
Background technique
Nutrition Science and Technology Co., Ltd. discloses one kind in Chinese patent 201810508103.7 and has at the beginning of people from Jiangxi
Help alleviate blue ray radiation injury composition and its application, comprising 2000 parts~8000 parts of docosahexaenoic acid (DHA) powder,
2 parts~200 parts of lutein substance, 1 part~100 parts of zeaxanthin ((3R, 3'R)-dihydroxy-beta carotene), rain life are red
100 parts~5000 parts of ball algae, 20~2000 parts of cyanidin extract and 300 parts~1400 parts of taurine.Help to alleviate blue light
Radiation injury.
Hunan Aoyou Food and Nutrition Research Institute discloses a kind of containing lutein in Chinese patent 201010208565.0
Baby milk powder and preparation method thereof, comprising raw material milk powder 100g, 0.01~0.05g of nucleotide, lutein crystal 0.01~
0.04g, 0.2~0.8g of docosahexaenoic acid, 0.3~1.0g of arachidonic acid.
Fujian Normal University disclosed in Chinese patent 201610339606.7 a kind of Olive oil microcapsule powder and its
Preparation method includes 30~80 parts of core material;0.5~3 part of emulsifier;1~10 part of wall material;The core material is olive oil;Wall material is
One or more of maltodextrin, cyclodextrin, pure glue, Arabic gum, casein sodium;Emulsifier is emulsifier selected from single sweet
Rouge, single, double stearine, sucrose ester, sorbitan monostearate, sorbitol monooleate, polyoxyethylene sorbitol
One of monoleate, egg yolk lecithin, soybean lecithin are several.Its technique is mixing after water phase is prepared respectively with oily phase,
It is just emulsified by 10000-20000r/min high shear, then handles the high-pressure homogeneous of 2 20~40MPa.Olive obtained by the invention
Oil microcapsule powder encapsulation ratio reaches 95% or more.
It is well known that lutein, which has, promotes dark adaptation ability, alleviate visual fatigue, resists blue light damage, alleviate glycosuria
Sick retinopathy improves visual adaptation ability, improves Age related macular portion lesion, reduces incidence of cataract, promotes vision
Discriminating function etc..The approach that lutein is metabolized in vivo are as follows: lutein is dissolved into mixed micelle after entering stomach, small intestine, is turned
It moves on to intestinal epithelial cell to be absorbed, target organ is transported in the circulatory system.The bioavailability of lutein in vivo is eaten
The influence of object matrix, lipid, food process processing method, in some cases, the content of food Lutein are not given birth to it
Object utilization rate is positively correlated, if the other compositions in opposite food form certain micellas with lutein in small enteral and may press down
The absorption of lutein processed.
Summary of the invention
The present invention is directed to overcome the deficiencies of the prior art and provide composition of a kind of protection eyesight and preparation method thereof and answer
With.
In order to achieve the above object, technical solution provided by the invention are as follows:
It is described protection eyesight composition include following parts by weight component: lutein 0.1~5, taurine 1~10,
DHA1~15, olive oil 1~15.
Microcapsules based on above-mentioned composition are made of core material and wall material, the parts by weight of the core material and wall material are as follows: core material
20~60, wall material 40~80;The core material is composition described in claim 1;The wall material is by colloid and lactalbumin group
At the mass percentage content of lactalbumin is 20~50% in the wall material.
Preferably, the colloid in Arabic gum, gelatin, starch octenyl succinate anhydride or maltodextrin at least
It is a kind of.
Preferably, the lactalbumin is selected from least one of milk albumin or sheep lactalbumin.
The above-mentioned preparation method for stating microcapsules includes the following steps:
(1) it prepares wall material: obtaining wall material after lactalbumin and colloid are mixed in above-mentioned ratio;
(2) water dissolution and is kept the temperature wall material: by wall material and distilled water 1:(3.5~6 in mass ratio) mix after, in 40~60 DEG C
30~90min is kept the temperature in water-bath;
(3) it prepares core material: obtaining core material after lutein, taurine, DHA, olive oil are mixed in above-mentioned ratio;
(4) core material is kept the temperature: by core material in 15~30min of heat preservation in 20~35 DEG C of water-baths;
(5) by after isothermal holding wall material and core material stir 5~8min after, with the revolving speed high shear of 900~2000r/min
(just emulsification) 60~120s, it is then high-pressure homogeneous then spray-dried under the conditions of 25~45MPa of pressure, 50~65 DEG C of temperature
After be filled with inert gas and nitrogen to get microcapsules finished product.
Preferably, step (5) spray drying is using high-pressure spray-drying, and control inlet air temperature is 140~190
DEG C, atomizing pressure be 5MPa~10MPa, temperature of outgoing air is 75~85 DEG C.
Composition and microcapsules of the present invention can be used for preparing the food of protection eyesight, especially goat milk product.It is excellent
The weight of selection of land, the composition or microcapsules accounts for the 0.1~6% of food weight.It is highly preferred that the composition or microcapsules
Weight account for the 0.3~6% of food weight.
The invention will be further described below:
The absorptivity and food matrix of lutein have much relations, dietary fiber and polyunsaturated fatty acid and certain classes
The effect that carrotene can inhibit lutein to absorb, and monounsaturated fatty acids can promote lutein bioavailability.This hair
It is bright that lutein, taurine, the merging of DHA group are dissolved in olive oil, then are fabricated to one kind by embedding techniques and may be added to that food
Microcapsules in product.The main component of grease microcapsule wall material is protein and carbohydrate, and wherein protein has hydrophilic, close
Oil base group can play emulsifier effect in grease microcapsule emulsification system stroke, reduce the interfacial tension of water phase and oily phase,
Stable oil-in-water system is formed, the existing good emulsibility of the hydrophilic gel class in carbohydrate, compounding with protein makes
With the compactness that grease microcapsule mill can be improved, enhances the mechanical strength of microcapsule membrane, prevent core material grease in storage process
Infiltration and oxidation.And in microcapsules preparation process, emulsification is committed step, but if emulsification condition requirement is very high, although having
Help improve embedding rate, but is unfavorable for industrialization production.Therefore suitable emulsification parameter is particularly important.
Compared with prior art, the invention has the benefit that
The composition of protection eyesight of the present invention has superior protection vision performance.Core material in the microcapsules being fabricated to
The synergy for resisting blue light damage has been not only acted as, the bioavailability of lutein is also improved.The wall material of microcapsules is selected
Colloid and lactalbumin combine, and not only embedding rate is high (embedding rate up to 92%), and film forming is good when dry, and surface oil is low, and
Core material rate of release in enteron aisle digestion process is reasonable.
Detailed description of the invention
Fig. 1 is nitric oxide level figure in rat blood serum after blue light illumination;
Fig. 2 is rat blood serum glutathione s-transferase (GST) level view after blue light illumination;
Fig. 3 is rat blood serum catalase (CAT) level view after blue light illumination;
Fig. 4 is rat c reactive protein (CRP) level view after blue light illumination;
Fig. 5 is interleukin-1 beta (IL-1 β) level view after blue light illumination rat;
Fig. 6 is tumor necrosis factor α (TNF-α) level view after blue light illumination rat.
Specific embodiment
Embodiment 1
The microcapsules of protection eyesight: 55 parts of core material, 45 parts of wall material;
The preparation method is as follows:
Wall material ingredient: Arabic gum, starch octenyl succinate anhydride, sheep lactalbumin by weight 2,1,2 mix;
Water dissolves wall material: wall material is mixed with distilled water 1:3.5 in mass ratio;
Wall material heat preservation: wall material keeps the temperature 90min in 40 DEG C of water-baths after mixing with distilled water;
Core material ingredient: lutein, taurine, DHA, olive oil by weight 1,1,2,6 mixes;
Core material heat preservation: mixed core material keeps the temperature 30min in 20 DEG C of water-baths;
Stir and evenly mix: wall material and core material after heat preservation stir at low speed 8min;
High shear (just emulsification): with the revolving speed high shear 120s of 900r/min;
It is high-pressure homogeneous: 65 DEG C of homogenizing temperature, pressure 35MPa;
Spray drying: using high-pressure spray-drying, 180~190 DEG C of inlet air temperature, control atomizing pressure 8MPa~10MPa,
75~85 DEG C of temperature of outgoing air;Up to the microcapsules of protection eyesight.
Embodiment 2
The microcapsules of protection eyesight: 30 parts of core material, 70 parts of wall material;
The preparation method is as follows:
Wall material ingredient: maltodextrin, milk albumin, sheep lactalbumin by weight 6,2,1 mix;
Water dissolves wall material: wall material is mixed with distilled water 1:4 in mass ratio;
Wall material heat preservation: wall material keeps the temperature 30min in 60 DEG C of water-baths after mixing with distilled water;
Core material ingredient: lutein, taurine, DHA, olive oil by weight 2,1,1,6 mixes;
Core material heat preservation: mixed core material keeps the temperature 15min in 35 DEG C of water-baths;
Stir and evenly mix: wall material and core material after heat preservation stir at low speed 5min;
High shear (just emulsification): with the revolving speed high shear 60s of 2000r/min;
It is high-pressure homogeneous: 50 DEG C of homogenizing temperature, pressure 45MPa;
Spray drying: using high-pressure spray-drying, 140~160 DEG C of inlet air temperature, control atomizing pressure 5MPa~7MPa,
75~85 DEG C of temperature of outgoing air;Up to the microcapsules of protection eyesight.
Embodiment 3
The microcapsules of protection eyesight: 20 parts of core material, 80 parts of wall material;
The preparation method is as follows:
Wall material ingredient: starch octenyl succinate anhydride, gelatin, milk albumin, sheep lactalbumin by weight 2,3,
2.5,1.5 mixing;
Water dissolves wall material: wall material is mixed with distilled water 1:6 in mass ratio;
Wall material heat preservation: wall material keeps the temperature 80min in 45 DEG C of water-baths after mixing with distilled water;
Core material ingredient: lutein, taurine, DHA, olive oil by weight 0.5,1,3,5.5 mixes;
Core material heat preservation: mixed core material keeps the temperature 20min in 25 DEG C of water-baths;
It stirs and evenly mixs: after wall material and core material after heat preservation stir at low speed 6min;
High shear (just emulsification): with the revolving speed high shear 100s of 1200r/min;
It is high-pressure homogeneous: 55 DEG C of homogenizing temperature, pressure 25MPa;
Spray drying: using high-pressure spray-drying, 160~170 DEG C of inlet air temperature, control atomizing pressure 6MPa~8MPa,
75~85 DEG C of temperature of outgoing air;Up to the microcapsules of protection eyesight.
Embodiment 4
The microcapsules of protection eyesight: 60 parts of core material, 40 parts of wall material;
The preparation method is as follows:
Wall material ingredient: Arabic gum and sheep lactalbumin by weight 3.5,1 mix;
Water dissolves wall material: wall material is mixed with distilled water 1:5 in mass ratio;
Wall material heat preservation: wall material keeps the temperature 30~90min after mixing with distilled water in 40~60 DEG C of water-baths;
Core material ingredient: lutein, taurine, DHA, olive oil by weight 2,2,3,3 mixes;
Core material heat preservation: mixed core material keeps the temperature 25min in 30 DEG C of water-baths.
Stir and evenly mix: wall material and core material after heat preservation stir at low speed 7min
High shear (just emulsification): with the revolving speed high shear 100s of 1000r/min.
It is high-pressure homogeneous: 58 DEG C of homogenizing temperature, pressure 30MPa
Spray drying: using high-pressure spray-drying, 140~190 DEG C of inlet air temperature, control atomizing pressure 5MPa~10MPa,
75~85 DEG C of temperature of outgoing air;Up to the microcapsules of protection eyesight.
Comparative example 1
This comparative example provides a kind of microcapsules for protecting eyesight, and the difference with embodiment 1 is only that wall material without sheep whey
Albumen, and 0.5 part of single, double stearine is added as emulsifier, remaining formula and technique are constant.
Comparative example 2
This comparative example provides a kind of microcapsules for protecting eyesight, and the difference with embodiment 1 is only that high shear (just emulsification)
Condition is 15000r/min, 60s;Processing condition is 15~50min of first time homogenizing time, and homogenization pressure is 20~40Mpa, the
The second homogenate time is 15~50min, and homogenization pressure is 20~50Mpa.
Comparative example 3
This comparative example provides a kind of microcapsules for protecting eyesight, and the difference with embodiment 1 is only that core material is free of olive oil,
Remaining formula and technique are constant.
Comparative example 4
This comparative example provides a kind of microcapsules for protecting eyesight, and the difference with embodiment 1 is only that core material is free of DHA,
Remaining formula and technique are constant.
Comparative example 5
This comparative example provides a kind of microcapsules for protecting eyesight, and the difference with embodiment 1 is only that core material is free of taurine,
Remaining formula and technique are constant.
Comparative example 6
This comparative example provides a kind of microcapsules for protecting eyesight, and the difference with embodiment 1 is only that core material without taurine
And DHA, remaining formula and technique are constant.
Comparative example 7
This comparative example provides a kind of microcapsules for protecting eyesight, and the difference with embodiment 1 is only that the lutein in core material
Change zeaxanthin into, remaining formula and technique are constant.
Comparative example 8
This comparative example provides a kind of microcapsules for protecting eyesight, and the difference with embodiment 1 is only that the lutein in core material
Change lutein ester into, remaining formula and technique are constant.
Comparative example 9
This comparative example provides a kind of microcapsules for protecting eyesight, and the difference with embodiment 1 is only that also containing in core material
Zeaxanthin and lutein ester, lutein, zeaxanthin, lutein ester, taurine, DHA, olive oil by weight 0.33,
0.33,0.33,1,2,6 mixing, remaining formula and technique are constant.
The microcapsules grease embedding rate, lutein embedding rate, taurine for investigating Examples 1 to 4 and comparative example 1~2 embed
The oxidation stability (table 1) of rate and microcapsules
1 microcapsules grease embedding rate (%) of table=[1- (total oil in surface oil/product)] × 100
Comparative example 1 | Comparative example 2 | Embodiment 1 | Embodiment 2 | Embodiment 3 | Embodiment 4 | |
Surface oil % | 3.6 | 2.87 | 1.82 | 1.03 | 0.81 | 1.48 |
Total oil % | 43.87 | 43.8 | 43.82 | 20.67 | 16.95 | 35.55 |
Grease embedding rate % | 91.79 | 93.45 | 95.85 | 95.02 | 95.22 | 95.84 |
2 lutein embedding rate % of table: microcapsules Lutein actual measured value/theoretical value * 100
Comparative example 1 | Comparative example 2 | Embodiment 1 | Embodiment 2 | Embodiment 3 | Embodiment 4 | |
Lutein embedding rate % | 83.82 | 87.73 | 94.18 | 93.67 | 90.00 | 90.58 |
3 taurine embedding rate % of table: taurine actual measured value/theoretical value * 100 in microcapsules
Comparative example 1 | Comparative example 2 | Embodiment 1 | Embodiment 2 | Embodiment 3 | Embodiment 4 | |
Taurine embedding rate % | 83.09 | 89.91 | 92.00 | 92.67 | 90.50 | 94.42 |
By above three table, it is found that Examples 1 to 4 is with comparative example 2, the difference on embedding rate is little, but is superior to comparative example 1,
Illustrate that wall material selection colloid and protein combination have preferable embedding rate, for comparative example 2 compared with Examples 1 to 4, embedding rate is poor
It is different not significant, illustrate emulsification condition of the invention also and can have good embedding effect.
The microcapsules application of the protection eyesight of embodiment 5
1 method
Investigate the protective effect of embodiment 1 and the damage of 3~6 pairs of rat retina blue lights of comparative example
SD rat 36, male, 8 week old are unified to raise, and animal every 4 are a cage, animal indoor illumination intensity 150lx,
12 hours light and shade circulations, are fed with using normal diet, freely obtain drinking-water.
Using random digits table by 56 SD rats, it is randomly divided into 9 groups: Normal group (without any processing), mould
Type control group (using blue light modeling), contrast groups 3 (comparative example 3), contrast groups 4 (comparative example 4), contrast groups 5 (comparative example 5), comparison
6 (comparative examples 6) of group, contrast groups 7 (comparative example 7), contrast groups 8 (comparative example 8), contrast groups 9 (comparative example 9), experimental group 1 (are implemented
Example 1), stomach-filling is soluble in water by respective substance respectively, raises 30 days by the stomach-filling amount of 1g/ pcs/day of stomach-filling.It is put into after raising
The dark adaptation that 24 hours are carried out in darkroom, place into blue light damage instrument in carry out 1.5h light exposure, after rat is sent back to secretly
It is raised in room, measures its ERG after anaesthetizing after 72h, then directly put to death, extract eyeball and remove retina.Light injury parameter: blue
Optical wavelength 452nm, 1400~1500lx of intensity.
2 measurement indexes
2.1 electroretinogram
Electroretinogram (ERG) the reaction retinal function under the conditions of dark adaptation is measured, delay time, A wave and B vibration are measured
Width.
2.2 serum and retina biochemical indicator
2.2.1 oxidative stress measures
It is horizontal that ELISA method measures serum levels of nitric oxide (NO).
2.2.2 Antioxidant Indexes are horizontal
It is horizontal that ELISA method measures serum GST, CAT.
2.2.3 inflammatory reaction index of correlation
It is horizontal that ELISA method measures serum CA125, IL-1 β, TNF-α.
3, result
The variation (being shown in Table 4) of rat retina electrograph after 3.1 blue light illuminations
Variation of 4 blue light of table according to rear rat retina electrograph
Group | Rod-a | Rod-b | Max-a | Max-b |
Normal group | -11.4±14.71 | 78.90±19.94 | -84.45±5.30 | 245.65±18.60 |
Model control group | -3.05±2.82 | 9.62±0.68 | -3.18±0.30 | 49.04±1.62 |
Contrast groups 3 | -3.80±061 | 8.07±3.43 | -2.37±11.59 | 36.20±21.28 |
Contrast groups 4 | -5.43±2.72 | 19.73±6.21 | -13.13±7.69 | 57.13±21.29 |
Contrast groups 5 | -5.06±1.78 | 22.60±7.32 | -21.37±8.46 | 81.20±37.90 |
Contrast groups 6 | -4.38±1.73 | 23.00±11.76 | -24.45±9.20 | 83.15±34.75 |
Contrast groups 7 | -2.17±2.93 | 15.47±3.74 | -19.20±6.55 | 61.20±23.40 |
Contrast groups 8 | -2.05±3.54 | 21.05±14.64 | -22.82±8.98 | 80.65±32.44 |
Contrast groups 9 | -4.80±0.00 | 16.35±7.57 | -16.50±8.74 | 53.00±38.75 |
Experimental group 1 | -6.53±2.78 | 54.10±36.80 | -47.80±34.59 | 170.07±128.00 |
Table 4 the result shows that, compared with Normal group, model control group, contrast groups and experimental group Rod react a wave, b wave
Wave amplitude significantly reduces.Max reacts a wave, b wave wave amplitude significantly reduces.Experimental group Rod reacts a wave, b wave, and Max reacts a wave, b
Wave amplitude is significantly raised compared with model control group and contrast groups, illustrates that formula plays synergy.
The variation of rat blood serum oxidative stress after 3.2 blue light illuminations
Fig. 1 shows: model control group serum levels of nitric oxide (NO) level significantly increases compared with Normal group, and each group
It is found after intervening, compared with model control group, the level of each group serum levels of nitric oxide is all had dropped, and wherein experimental group 1 is significant
Decline.
The variation of rat blood serum antioxidase after 3.3 blue light illuminations
Fig. 2 and Fig. 3 be as the result is shown: after rat receives blue light illumination, model control group Serum glutathione S transferase
(GST), the content of catalase (CAT) reduces.After intervening, the study find that, compared with model control group, Ge Gegan
Pre- group serum GST and CAT increased compared with model control group, and experimental group 1 obviously increases.Illustrate micro- glue of the invention
The antioxidation of capsule.
The variation of rat blood serum inflammatory factor after 3.4 blue light illuminations
Fig. 4, Fig. 5 and Fig. 6 the result shows that: after rat receives blue light illumination, compared with Normal group, model control group blood
In clear inflammatory levels improve, and c reactive protein (CRP), interleukin-1 beta (IL-1 β), tumor necrosis factor α (TNF-α) contain
Amount significantly increases.After intervening, c reactive protein (CRP), interleukin-1 beta (IL-1 β), tumor necrosis factor α in serum
(TNF-α) has decline in each group, but compared with the control group, and experimental group effect is more significant, it is shown that the micro- glue of the lutein
Capsule resists the effect of blue light damage.
Claims (10)
1. a kind of composition for protecting eyesight, which is characterized in that the composition includes the component of following parts by weight: lutein
0.1~5, taurine 1~10, DHA1~15, olive oil 1~15.
2. a kind of microcapsules based on composition described in claim 1, which is characterized in that the microcapsules are by core material and wall material group
At the parts by weight of the core material and wall material are as follows: core material 20~60, wall material 40~80;The core material is described in claim 1 group
Close object;The wall material is made of colloid and lactalbumin, in the wall material mass percentage content of lactalbumin be 20~
50%.
3. microcapsules as claimed in claim 2, which is characterized in that the colloid is selected from Arabic gum, gelatin, octenyl succinic
At least one of acid-starch ester or maltodextrin.
4. microcapsules as claimed in claim 3, which is characterized in that the lactalbumin is selected from milk albumin or sheep whey
At least one of albumen.
5. the preparation method of microcapsules as described in any one of claim 2 to 4, which is characterized in that the method includes walking as follows
It is rapid:
(1) it prepares wall material: obtaining wall material after lactalbumin and colloid ratio as described in claim 2 are mixed;
(2) water dissolution and is kept the temperature wall material: by wall material and distilled water 1:(3.5~6 in mass ratio) mix after, in 40~60 DEG C of water-baths
30~90min of middle heat preservation;
(3) it prepares core material: obtaining core material after lutein, taurine, DHA, olive oil ratio according to claim 1 are mixed;
(4) core material is kept the temperature: by core material in 15~30min of heat preservation in 20~35 DEG C of water-baths;
(5) by after isothermal holding wall material and core material stir 5~8min after, with the revolving speed high shear 60 of 900~2000r/min~
120s, it is then high-pressure homogeneous under the conditions of 25~45MPa of pressure, 50~65 DEG C of temperature, then it is spray-dried after be filled with indifferent gas
Body and nitrogen are to get microcapsules finished product.
6. method as claimed in claim 5, which is characterized in that step (5) spray drying is to use high-pressure spray-drying,
Control inlet air temperature is 140~190 DEG C, atomizing pressure is 5MPa~10MPa, temperature of outgoing air is 75~85 DEG C.
7. the application of composition as described in claim 1 or microcapsules described in requiring 3 in the food of preparation protection eyesight.
8. application as claimed in claim 2, which is characterized in that the food is goat milk product.
9. application as claimed in claim 8, which is characterized in that the weight of the composition or microcapsules accounts for food weight
0.1~6%.
10. application as claimed in claim 9, which is characterized in that the weight of the composition or microcapsules accounts for food weight
0.3~6%.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201910551905.0A CN110236189A (en) | 2019-06-25 | 2019-06-25 | A kind of composition and its preparation method and application for protecting eyesight |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201910551905.0A CN110236189A (en) | 2019-06-25 | 2019-06-25 | A kind of composition and its preparation method and application for protecting eyesight |
Publications (1)
Publication Number | Publication Date |
---|---|
CN110236189A true CN110236189A (en) | 2019-09-17 |
Family
ID=67889145
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201910551905.0A Pending CN110236189A (en) | 2019-06-25 | 2019-06-25 | A kind of composition and its preparation method and application for protecting eyesight |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN110236189A (en) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN114271499A (en) * | 2021-12-29 | 2022-04-05 | 江南大学 | Microcapsule powder with high embedding rate and preparation method thereof |
CN114376229A (en) * | 2022-01-19 | 2022-04-22 | 中国科学院兰州化学物理研究所 | Microcapsule using medlar fruit oil and olive oil as core materials |
WO2024055795A1 (en) * | 2022-09-16 | 2024-03-21 | 大连工业大学 | Medicine and food dual-purpose composition capable of resisting blue light damage to retina, preparation method therefor, and use thereof |
Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20070098849A1 (en) * | 2005-10-26 | 2007-05-03 | Bridget Barrett-Reis | Infant formulas containing docosahexaenoic acid and lutein |
US20120258168A1 (en) * | 2011-04-07 | 2012-10-11 | Amerisciences, Lp | Methods and compositions to promote ocular health |
CN103735532A (en) * | 2014-01-15 | 2014-04-23 | 山东星光生物科技有限公司 | Lutein ester microcapsule and preparation method thereof |
WO2016124783A1 (en) * | 2015-02-06 | 2016-08-11 | Basf Se | Microcapsules comprising lutein or lutein ester |
CN105942525A (en) * | 2016-05-20 | 2016-09-21 | 福建师范大学 | Olive oil microcapsule powder and preparation method thereof |
CN107660620A (en) * | 2017-08-29 | 2018-02-06 | 湖北欣和生物科技有限公司 | A kind of sheep base oil grease microcapsule powder and preparation method thereof |
CN108065443A (en) * | 2017-12-30 | 2018-05-25 | 厦门金达威维生素有限公司 | Hydrophobic double coated microcapsules of type and preparation method thereof |
-
2019
- 2019-06-25 CN CN201910551905.0A patent/CN110236189A/en active Pending
Patent Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20070098849A1 (en) * | 2005-10-26 | 2007-05-03 | Bridget Barrett-Reis | Infant formulas containing docosahexaenoic acid and lutein |
US20120258168A1 (en) * | 2011-04-07 | 2012-10-11 | Amerisciences, Lp | Methods and compositions to promote ocular health |
CN103735532A (en) * | 2014-01-15 | 2014-04-23 | 山东星光生物科技有限公司 | Lutein ester microcapsule and preparation method thereof |
WO2016124783A1 (en) * | 2015-02-06 | 2016-08-11 | Basf Se | Microcapsules comprising lutein or lutein ester |
CN105942525A (en) * | 2016-05-20 | 2016-09-21 | 福建师范大学 | Olive oil microcapsule powder and preparation method thereof |
CN107660620A (en) * | 2017-08-29 | 2018-02-06 | 湖北欣和生物科技有限公司 | A kind of sheep base oil grease microcapsule powder and preparation method thereof |
CN108065443A (en) * | 2017-12-30 | 2018-05-25 | 厦门金达威维生素有限公司 | Hydrophobic double coated microcapsules of type and preparation method thereof |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN114271499A (en) * | 2021-12-29 | 2022-04-05 | 江南大学 | Microcapsule powder with high embedding rate and preparation method thereof |
CN114376229A (en) * | 2022-01-19 | 2022-04-22 | 中国科学院兰州化学物理研究所 | Microcapsule using medlar fruit oil and olive oil as core materials |
WO2024055795A1 (en) * | 2022-09-16 | 2024-03-21 | 大连工业大学 | Medicine and food dual-purpose composition capable of resisting blue light damage to retina, preparation method therefor, and use thereof |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN108430461B (en) | Preparation method of high-stability microcapsule dry powder/particles containing fat-soluble nutrients with more double bonds | |
CN110236189A (en) | A kind of composition and its preparation method and application for protecting eyesight | |
Ren et al. | The interactions between anthocyanin and whey protein: A review | |
CN108720021A (en) | DHA algal oil microscapsule powder and preparation method thereof | |
CN105613789A (en) | High-fat and high-dietary-fiber composite animal and plant powdered oil and preparation method and application thereof | |
CN106666714B (en) | Sugar-free beta-carotene microcapsule and preparation method thereof | |
CN113115945B (en) | Lutein compound microcapsule powder and preparation method and application thereof | |
KR102409377B1 (en) | Composition for improving dry eyes and preventing tear pigmentation for pets | |
CN108308615A (en) | A kind of corn peptide is the preparation method of the lutein nanometer grain of carrier | |
CN109158061A (en) | A kind of capsanthin microcapsule and the preparation method and application thereof | |
CN109198641A (en) | A kind of food formula and shellproof coffee prepared therefrom of low carbohydrate content | |
CN109157510A (en) | A kind of water-soluble carotenoid preparation and the preparation method and application thereof | |
CN107969506A (en) | A kind of high stability fish oil breast for improving glycometabolism and preparation method thereof | |
JPS63123354A (en) | Prepared liquid nutritious composition for glucose intolerant patient | |
CN104323283B (en) | Contain alimentation composition of Co-Q10 and preparation method thereof and application | |
CN114081096A (en) | Preparation method of milk protein loaded astaxanthin emulsion combined with polyphenol and glycosylation modification | |
CN105030877A (en) | Healthcare food for relieving asthenopia and preparation method thereof | |
CN107410811B (en) | Preparation method of lutein microcapsule and lutein microcapsule instant beverage | |
CN101947214A (en) | Method for preparing vitamin A microcapsules by secondary emulsification and spray drying method | |
CN109123659A (en) | A kind of walnut protein composite powder and preparation method thereof for diatery supplement nutriment | |
CN106962916A (en) | The Microencapsulation Method of gingko ferment microencapsulated products and gingko ferment | |
CN101999652A (en) | Blood fat-reducing health-care food and preparation method thereof | |
CN112042937A (en) | Water-soluble lutein emulsion gel and preparation method thereof | |
CN102038644A (en) | Lutein water-soluble powder and preparation process thereof | |
AU2021103800A4 (en) | Controlled-Released Lutein Emulsion Gel and Formulation Thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
RJ01 | Rejection of invention patent application after publication |
Application publication date: 20190917 |
|
RJ01 | Rejection of invention patent application after publication |